% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • boulder_56 boulder_56 Sep 20, 2005 2:51 PM Flag

    Bankruptcy is Strong Possibility

    falling Taxus revenue coupled with the 'Litigation Levee' failing could see a bond default and banks calling the $800mm out there.

    <<might be happening right now folks>>

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "We will definitly have to retest the $22.75 area unfortunately"

      How many times have you posted this lie, 100?

      Do you have a daemon do it for you or do you sit there and poke the buttons with your grubby little hands???

    • "We will definitly have to retest the $22.75 area unfortunately"

      How many times have you posted this lie, 100?

      Do you have a daemon do it for you or do you sit there and poke the buttons with your grubby little hands???

    • We will definitly have to retest the $22.75 area unfortunately. Hopefully we hold support at $22.75 or it could even go lower than that, but the charts don't lie about these things unfortunatly, charts are bearish again, but we will definitely have to retest,then we will see if it heads lower or forms a double bottom then comes back with volume at about $22.
      In other news...
      U.S. Trade Deficit Reaches All-Time High
      Thursday December 15, 12:15 am ET
      By Martin Crutsinger, AP Economics Writer
      Surge in Oil Imports Helps Drive U.S. Trade Deficit to All-Time High in October

      WASHINGTON (AP) -- A surge in oil imports and a flood of Chinese televisions, toys and computers helped to drive the U.S. trade deficit to an all-time high in October.

      The Commerce Department reported Wednesday that the gap between what America sells overseas and what it imports rose by 4.4 percent to $68.9 billion, surpassing the record of $66 billion set in September.

      The worse-than-expected October performance was blamed in part on the Gulf Coast hurricanes. They curtailed domestic production of oil, chemicals and plastics, forcing companies to turn to overseas suppliers.

      Month after month, we see new record trade deficits that spell real trouble for the United States," said Sen. Byron Dorgan, D-N.D. "Behind these deficits are massive numbers of American jobs lost to foreign countries

      "We just don't see how current U.S. strategy is going to reverse these very dangerous trends," said Alan Tonelson, a research fellow at the U.S. Business and Industry Council. The group represents mainly small U.S. manufacturing companies.

    • How long did you LOVE BSX? Two weeks? HA Ha HA
      Good one. Really, more creative than most slammers. You're up for an Oscar.

    • disaster_strikes_thrice disaster_strikes_thrice Dec 26, 2005 10:06 PM Flag

      Ha Ha funny, and do you also like the massive share dilution, and $12 billion in debt?

    • Hopefully when they lose the 6 class action lawsuits the FDA will impose fines at least. This company seems to not care about human life at all they have been warned numerous times and yet they continue to put out products that are killing people. FDA really needs to shut the doors on this death factory.

      I am very disapointed in BSX management and products. I know that people have died because of their neglegence, and I will be joining the class action lawsuit to get money back that I have lost from being a former holder. BSX has clearly been shown to put out defective products more than others.
      Studies Give Edge To J&J Stent
      Matthew Herper
      NEW YORK - Johnson & Johnson has a better product than its rival, Boston Scientific, for holding open clogged arteries.

      New data published in the two leading medical journals indicates that patients who receive Cypher, a drug-coated stent made by Johnson & Johnson (nyse: JNJ - news - people ), are far less likely to need a repeat surgery than those who get Taxus, a rivalstent from Boston Scientific (nyse: BSX - news - people ).

      That's more bad news for Boston Scientific, which has seen shares drop 30% since September 2004 amid concerns over its over-reliance on drug-coated stents.

      "There is a difference," says David J. Moliterno, a cardiologist at the University of Kentucky who wrote an editorial on the studies in The New England Journal of Medicine.
      For all patients taken as a group, Moliterno says, those who receive Taxus are much more likely to need their procedure redone than those who receive Cypher.

      High-risk patients, such as those with diabetes, also fare better with the Cypher stent, he says.

      Samin Sharma, a cardiologist at the Mount Sinai School of Medicine, say she thinks most doctors would opt to use Cypher if it weren't for persistent manufacturing problems that can make the device harder for doctors to get. He notes that the evidence is consistent that Cypher is better at preventing arteries from reclogging.

      The researchers found that patients receiving Cypher were at much lower risk of having their arteries reclose than those who received Taxus. The results are published in the current issue of The Journal of the American Medical Association. Says Firth, "I think the value of this product from a health economics standpoint is very clearly demonstrated."

      Meanwhile, J&J says the U.S. Food and Drug Administration has visited new manufacturing plants that would finally allow it to churn out more Cypher stents--and it is waiting for the OK to start the assembly lines running.

    • Your lucky to get out above $23. This garbage sinks fast, I hate to see anybody holding the shares the insiders are dumping. This thing will drop like a whale turd when people realize they don't have the money to pay all these leagal fees and have to borrow more, just to pay the lawsuits. The FDA seriously needs to hurry up and force the removal of Taxus or impose fines at least, all the patient deaths can't continue, the FDA has a responsibility to protect consumers.
      Doctors have continued reporting injuries during the implantation of cardiac stents made by Boston Scientific Corp., many of them linked to a problem that preceded a voluntary temporary recall of the devices last year.

      Balloons used to deploy the stents -- small, wire-mesh tubes inserted into clogged arteries to open them up -- failed to deflate or were so hard to remove that three people died and dozens more were injured during operations performed after the 2004 recall, according to Food and Drug Administration records.

      A review of the FDA data shows that between last Oct. 1 and April 1, the agency received at least 45 reports of deflation difficulties with Boston Scientific stent balloons. In 86 other cases, doctors reported that the balloons became stuck or otherwise were difficult to withdraw from a patient's body.

      The problems leading to injuries were detailed in "adverse event" reports submitted to the FDA voluntarily by doctors. In most cases, those reports came through the company, as often happens.

    • Same old lying bullsh*t, with a big steaming pile of CONR pumping thrown in for good measure...

    • CONR has a better mousetrap. BSX obsolete.
      Conor Medsystems is set to take on Boston Scientific
      Medsystems Inc. (CONR ) has developed a new better breed of stent that have the power to swipe large swaths of business from rivals such as Johnson & Johnson (JNJ ) and Boston Scientific Corp. (BSX )
      J&J and Boston Scientific are the two gladiators in this field, but many physicians are keeping a close eye on Conor's product as well. Although the stent's rate of restenosis, or recurrence of arterial blockages, has been much better than Boston Scientifics, doctors say Conor's is also easier to implant is also safer and more effective.

      The Menlo Park (Calif.) company will release new data from clinical trials at a top cardiovascular meeting in Washington. "If it came out in the U.S. right now, the market would swing," says Dr. Dean Kereiakes, a professor of clinical medicine at Ohio State University who is serving as a co-principal investigator for Conor's U.S. clinical trial.

      Conor has had some success but CIBC analyst John P. Calcagnini, who has a $26 price target on the stock, believes Conor can take 11% of the market by 2006.

      Angiotech licenses a drug called paclitaxel to Boston Scientific that inhibits the growth of scar tissue. Conor uses the same drug in its clinical trials, but the way it incorporates and releases the drug is novel and doesn't infringe on its rivals' patents.

      Litvack has helped run three companies, one of which was Advanced Interventional Systems Inc. The company developed laser technology to clear up artery blockages, In 1994 it was acquired by its chief rival, Spectranetics Corp. (SPNC ), for just $12 million -- a thin sliver of the $150 million market cap it reached after going public in 1991.

      At least two physicians with no financial ties to Conor give its device high marks. Some cardiologists say Conor may succeed because its stent, which is thinner and less sticky than existing drug-coated stents, is more easily maneuvered through a clogged artery. "If everything else was me-too, just that one feature would take the whole market," says Dr. Mitchell Krucoff, a professor of medicine and cardiology at Duke University Medical Center If current clinical trials go well, Conor must battle Boston Scientific, J&J, and others. Boston Scientific is spending more than $200 million a year on interest and debt. For Litvack, the key to beating the competition is more innovation, both in devices and drugs. Conor is now developing a stent that uses anti-clotting compounds acquired from Novartis. "We believe the job of a good medical company is to make your products obsolete," he says.

    • Only a fool would listen to this pig regarding the weekend. More good news coming debt upgrades ahead. The nonsense timber posts are only the tip of the iceburg of his/her/its stupidity.

    • View More Messages
17.80+0.10(+0.56%)Jul 1 4:00 PMEDT